208 related articles for article (PubMed ID: 27542273)
21. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
22. DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma.
Roberto GM; Paiva HH; Botelho de Souza LE; Pezuk JA; Vieira GM; de Oliveira HF; Umezawa K; Tone LG; Brassesco MS
Anticancer Agents Med Chem; 2018; 18(9):1323-1329. PubMed ID: 29683097
[TBL] [Abstract][Full Text] [Related]
23. The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells.
Bou-Gharios J; Assi S; Bahmad HF; Kharroubi H; Araji T; Chalhoub RM; Ballout F; Harati H; Fares Y; Abou-Kheir W
Pharmacol Rep; 2021 Feb; 73(1):227-239. PubMed ID: 33140310
[TBL] [Abstract][Full Text] [Related]
24. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib and lithium chloride combination treatment shows promising synergistic effects in human glioblastoma multiforme cells in vitro but midkine is not implicated.
Sabancι PA; Ergüven M; Yazιhan N; Aktaş E; Aras Y; Civelek E; Aydoseli A; Imer M; Gürtekin M; Bilir A
Neurol Res; 2014 Mar; 36(3):189-97. PubMed ID: 24512012
[TBL] [Abstract][Full Text] [Related]
27. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
28. Combination treatment for glioblastoma with temozolomide, DFMO and radiation.
Alexiou GA; Vartholomatos E; I Tsamis K; Peponi E; Markopoulos G; A Papathanasopoulou V; Tasiou I; Ragos V; Tsekeris P; Kyritsis AP; Galani V
J BUON; 2019; 24(1):397-404. PubMed ID: 30941997
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
30. Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture.
Burckel H; Josset E; Denis JM; Gueulette J; Slabbert J; Noël G; Bischoff P
Oncol Rep; 2015 Jan; 33(1):471-7. PubMed ID: 25371289
[TBL] [Abstract][Full Text] [Related]
31. Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells.
Aldea MD; Petrushev B; Soritau O; Tomuleasa CI; Berindan-Neagoe I; Filip AG; Chereches G; Cenariu M; Craciun L; Tatomir C; Florian IS; Crivii CB; Kacso G
J BUON; 2014; 19(2):502-11. PubMed ID: 24965413
[TBL] [Abstract][Full Text] [Related]
32. Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.
Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Miletic H; Enger PØ; Goplen D
J Neurooncol; 2016 Aug; 129(1):57-66. PubMed ID: 27283525
[TBL] [Abstract][Full Text] [Related]
33. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
[TBL] [Abstract][Full Text] [Related]
34. Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells.
Cui PH; Rawling T; Gillani TB; Bourget K; Wang XS; Zhou F; Murray M
Biochem Pharmacol; 2013 Aug; 86(3):419-27. PubMed ID: 23732299
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
Yi H; Ye X; Long B; Ye T; Zhang L; Yan F; Yang Y; Li L
Cancer Biother Radiopharm; 2017 Jun; 32(5):176-183. PubMed ID: 28622037
[TBL] [Abstract][Full Text] [Related]
36. Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells.
Muche S; Kirschnick M; Schwarz M; Braeuning A
Anticancer Res; 2014 Sep; 34(9):4677-83. PubMed ID: 25202044
[TBL] [Abstract][Full Text] [Related]
37. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
Atif F; Patel NR; Yousuf S; Stein DG
PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
[TBL] [Abstract][Full Text] [Related]
38. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
Fiorio Pla A; Brossa A; Bernardini M; Genova T; Grolez G; Villers A; Leroy X; Prevarskaya N; Gkika D; Bussolati B
BMC Cancer; 2014 Dec; 14():939. PubMed ID: 25494980
[TBL] [Abstract][Full Text] [Related]
39. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
[TBL] [Abstract][Full Text] [Related]
40. High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma.
Yu KK; Taylor JT; Pathmanaban ON; Youshani AS; Beyit D; Dutko-Gwozdz J; Benson R; Griffiths G; Peers I; Cueppens P; Telfer BA; Williams KJ; McBain C; Kamaly-Asl ID; Bigger BW
PLoS One; 2018; 13(3):e0193694. PubMed ID: 29499065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
